Kymera Therapeutics Inc’s filing revealed that its Director BVF PARTNERS L P/IL acquired Company’s shares for reported $13.96 million on Jun 30 ’25. In the deal valued at $44.00 per share,317,167 shares were bought. As a result of this transaction, BVF PARTNERS L P/IL now holds 2,798,795 shares worth roughly $120.26 million.
Then, BAKER BROS. ADVISORS LP bought 655,500 shares, generating $28,842,000 in total proceeds. Upon buying the shares at $44.00, the Director now owns 6,117,295 shares.
Before that, Ridloff Elena sold 4,500 shares. Kymera Therapeutics Inc shares valued at $225,000 were divested by the Director at a price of $50.00 per share. As a result of the transaction, Ridloff Elena now holds 0 shares, worth roughly $0.0.
Morgan Stanley also remained covering KYMR and has increased its forecast on June 03, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating. B. Riley Securities revised its rating on June 03, 2025. It rated KYMR as “a Buy” which previously was an “a Neutral”.
Price Performance Review of KYMR
On Tuesday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -1.58% to $42.97. Over the last five days, the stock has lost -1.67%. Kymera Therapeutics Inc shares have fallen nearly -3.42% since the year began. Nevertheless, the stocks have risen 6.81% over the past one year.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-07-15, dropping by 10253.0 shares to a total of 7.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 7.58 million shares. There was a decline of -0.14%, which implies that there is a negative sentiment for the stock.
